Evidence map›Paper›PMID 33169789›Full record

ArticleBioscience reports2020

Cytotoxic T-lymphocyte elicited therapeutic vaccine candidate targeting cancer against MAGE-A11 carcinogenic protein.

Neeraj Kumar, Damini Sood, Aditya Gupta, Niraj Kumar Jha, Pallavi Jain, Ramesh Chandra

Open access · goldAbstract readComparative Study
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Neeraj KumarDepartment of Chemistry, University of Delhi, Delhi 110007, India.
Damini SoodDepartment of Chemistry, University of Delhi, Delhi 110007, India.
Aditya GuptaThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology, Rochester, NY 14623, United States of America.
Niraj Kumar JhaDepartment of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, Uttar Pradesh 201310, India.
Pallavi JainDepartment of Chemistry, SRM Institute of Science and Technology, Delhi-NCR Campus, Ghaziabad, Uttar Pradesh 201204, India.
Ramesh ChandraDepartment of Chemistry, University of Delhi, Delhi 110007, India.
University of Delhi · INRochester Institute of Technology · USSharda University · INSRM Institute of Science and Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is a breakthrough approach for cancer treatment and prevention. By exploiting the fact that cancer cells have overexpression of tumor antigens responsible for its growth and progression, which can be identified and removed by boosting the immune system. In silico techniques have provided efficient ways for developing preventive measures to ward off cancer. Herein, we have designed a potent cytotoxic T-lymphocyte epitope to elicit a desirable immune response against carcinogenic melanoma-associated antigen-A11. Potent epitope was predicted using reliable algorithms and characterized by advanced computational avenue CABS molecular dynamics simulation, for full flexible binding with HLA-A*0201 and androgen receptor to large-scale rearrangements of the complex system. Results showed the potent immunogenic construct (KIIDLVHLL), from top epitopes using five algorithms. Molecular docking analyses showed the strong binding of epitope with HLA-A*0201 and androgen receptor with docking score of -780.6 and -641.06 kcal/mol, respectively. Molecular dynamics simulation analysis revealed strong binding of lead epitope with androgen receptor by involvement of 127 elements through atomic-model study. Full flexibility study showed stable binding of epitope with an average root mean square deviation (RMSD) 2.21 Å and maximum RMSD value of 6.48 Å in optimal cluster density area. The epitope also showed remarkable results with radius of gyration 23.0777 Å, world population coverage of 39.08% by immune epitope database, and transporter associated with antigen processing (TAP) affinity IC50 value of 2039.65 nm. Moreover, in silico cloning approach confirmed the expression and translation capacity of the construct within a suitable expression vector. The present study paves way for a potential immunogenic construct for prevention of cancer.

Indexed as

Cytotoxicity, ImmunologicDrug DesignEpitopes, T-LymphocyteAlgorithmsAntigens, NeoplasmCancer VaccinesHLA-A2 AntigenHumansImmunogenicity, VaccineMolecular Docking SimulationMolecular Dynamics SimulationNeoplasm ProteinsNeoplasmsProtein BindingReceptors, AndrogenT-Lymphocytes, CytotoxicAntigens, NeoplasmAR protein, humanCancer VaccinesEpitopes, T-LymphocyteHLA-A*02:01 antigenHLA-A2 AntigenMAGEA11 protein, humanNeoplasm ProteinsReceptors, AndrogenVaccines, SubunitCytotoxic T-cell epitopeFull Flexibility DynamicsImmunoinformaticsMolecular Docking SimulationPeptide Rearrangements

Identifiers

PMID33169789
PMCPMC7711063
OpenAlexW3106301909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.